The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a more substantial decrease in body weight and benefit metabolic function, parti